Steve Weinstein

Managing Member

2018

• Consulting and advisory to medtech, biotech and digital health start-ups.

Chairman

2019

• Next generation intravascular cardiology imaging combining DeepOCT™ imaging, near infrared spectroscopy (NIRS), and AI-powered insights to optimize coronary stenting and better inform care.

Strategic Advisor

2019

• Clinical research and commercial translation strategy related to mental health, neuomodulation, addiction, and digital tools in clinical practice.

Product Development Review Council Member

2018

Council reviews oncology-focused grants of up to $20M/company.

Board Member

2021

CEO

2021 - 2023

• Joined as Independent Director. Became Interim CEO to build senior leadership team including CSO, CMO, and Data Science. Developed new R&D and clinical strategy. • Development stage prostate cancer prognostic for monitoring patients with low risk tumors (Active Surveillance)

Board Member

2021

Developing an ingestible drug/device which detects and reverses opioid overdose.

Consultant, Neuroscience Innovation

2021 - 2024

• Developed best practices recommendations for corporate innovation. • Evaluate technologies and manage projects that transform the treatment of neurological diseases including neuromuscular, precision psychiatry, and drug delivery.

Interim COO

2019 - 2020

• Non-Profit Microbiome Research Institute; Collect process, and commercial FMT for CDiff. • Oversaw clinical research (IIT studies), finance, regulatory, and operations.

Interim CEO and Board Member

2018 - 2019

Clinical stage hypertension medical device.

Managing Director, Novartis Venture Fund

2006 - 2018

• Managed $800M global portfolio as one of eight Managing Directors (four US MDs). Led Medtech portfolio. • Investment partner for all investment decisions across the fund globally. Mentored junior colleagues. • Sourced and invested across all therapeutic areas and modalities, including medical device, biotech, and digital. • Invested across all stages including company formation, preclinical, clinical, and commercial. • Led scientific, clinical, and financial diligence, and structured investments as lead investor. • Built syndicates up to $45M, with NVF investment up to $25M over the life of a company. • Played an integral role in portfolio company oversight: executive recruitment, clinical/commercial strategy, governance, financing events, and exit/acquisition business development and negotiation. • Developed fund best practices, related to diligence, portfolio management, and fund cash flow management. • Representative Board of Directors and portfolio engagement: Ablation Frontiers (cardiac Afib, acquired Medtronic), Autonomic Technologies (neuromodulation), Cavion (essential tremor, Acquired Jazz), Celladon (heart failure, IPO), Innocrin (oncology), Sonitus (hearing), Symetis (cardiovascular, acquired Boston Scientific), Viamet (antifungal/women’s health, acquired Novaquest), Visiogen (ophthalmology, acquired Abbott). • Recruited Entrepreneur-In-Residence and evaluated NewCo development in ophthalmology. Clinical areas including: anti-infectives, cardiology, diabetes, diagnostics, immunology, otology, ophthalmology, oncology, respiratory, and neuroscience.